About Cell Theranostics
Our Company
Cell Theranostics is a late-stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases. It is the mission of Cell Theranostics to create better nuclear imaging and therapeutic agents that are affordable and accessible around the world.
Our Lead Product – Oncardia
Oncardia can be used to assess the patient’s response to therapy while undergoing therapy. This will give oncologists a valuable tool to determine if the patient is benefiting from the selected therapy or should the oncologist reconsider the choice of therapy. Oncardia was developed to address the limitations of FDG-PET (positron emission tomography) in cancer imaging while increasing access to cancer imaging to a significantly greater number of hospitals worldwide. Cell Theranostics is completing a Phase 3 trial for Oncardia in lung cancer under a Letter of Agreement with the FDA pursuant to a Special Protocol Assessment, and a Phase 2b cardiovascular trial in patients with coronary artery disease. The focus in cardiology is to assess the patient’s ischemia in a rest-only imaging procedure which will dramatically shorten the time required to complete the patient’s study and achieve noticeably greater diagnostic accuracy compared to the standard of care.
Lung Cancer Imaging
Cell Theranostics is sponsoring a Phase 3 lung cancer imaging trial for 99mTc-Oncardia under an FDA Letter Agreement based on an approved Special Protocol Assessment (“SPA”), and a Phase 2b/3 cardiovascular imaging trial for 99mTc-Oncardia to diagnose the presence and extent of coronary artery disease focusing specifically on myocardial ischemia in patients who have suffered a myocardial infarction. In therapy, the company is developing its first three therapeutic compounds, Platinum-Oncardia, 177Lu-Oncardia and 187Re-Oncardia.
Chelation Based Technologies
In addition to Ethylenedicysteine Drug Conjugate Technology platform compounds, Cell Theranostics is planning to increase its commitment to developing product compounds from its other chelation-based technologies to address diabetes, pancreatic cancer, neuroendocrine diseases and disorders, and the ability to perform single dose dual modality imaging and simultaneous chemo/radiation therapy.
Cell Theranostics and its lead product 99mTc-Oncardia have been featured on Fox News, Fox Business Channel, National Public Radio and local Denver Colorado affiliates of ABC, CBS and NBC.